These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35937691)

  • 1. Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia.
    Zhu Y; Tang Y; He H; Hu P; Sun W; Jin M; Wang L; Xu X
    Front Cell Infect Microbiol; 2022; 12():919352. PubMed ID: 35937691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prebiotic effects of soluble dietary fiber mixture on renal anemia and the gut microbiota in end-stage renal disease patients on maintenance hemodialysis: a prospective, randomized, placebo-controlled study.
    Li Y; Han M; Song J; Liu S; Wang Y; Su X; Wei K; Xu Z; Li H; Wang Z
    J Transl Med; 2022 Dec; 20(1):599. PubMed ID: 36517799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effects of Hemodialysis and Peritoneal Dialysis on the Gut Microbiota of End-Stage Renal Disease Patients, and the Relationship Between Gut Microbiota and Patient Prognoses.
    Luo D; Zhao W; Lin Z; Wu J; Lin H; Li Y; Song J; Zhang J; Peng H
    Front Cell Infect Microbiol; 2021; 11():579386. PubMed ID: 33834002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients.
    Kalantar-Zadeh K; McAllister CJ; Lehn RS; Lee GH; Nissenson AR; Kopple JD
    Am J Kidney Dis; 2003 Oct; 42(4):761-73. PubMed ID: 14520627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
    Fujita Y; Inoue S; Horiguchi S; Kuki A
    Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients.
    Ifudu O; Macey LJ; Friedman EA
    ASAIO J; 1995; 41(3):M426-30. PubMed ID: 8573839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
    Powe NR; Griffiths RI; Bass EB
    J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients.
    Canaud B; Polito-Bouloux C; Garred LJ; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Am J Kidney Dis; 1990 Feb; 15(2):169-75. PubMed ID: 2301388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of erythropoietin before the initiation of dialysis and its impact on mortality.
    Fink J; Blahut S; Reddy M; Light P
    Am J Kidney Dis; 2001 Feb; 37(2):348-55. PubMed ID: 11157377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.
    Wong HS; Chang CM; Kao CC; Hsu YW; Liu X; Chang WC; Wu MS; Chang WC
    J Biomed Sci; 2017 Jul; 24(1):43. PubMed ID: 28697735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
    Tarng DC; Huang TP; Doong TI
    Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of medical practice in the care of anemia amd the use of erythropoietin in chronic renal insufficiency hemodialysis in the past six years].
    Canaud B; Richard A; Fagnani F; Moreau-Defarges T; Guillon P
    Nephrologie; 2002; 23(3):123-30. PubMed ID: 12087809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality risk in hemodialysis patients according to anemia control and erythropoietin dosing.
    Santos PR; Melo AD; Lima MM; Negreiros IM; Miranda JS; Pontes LS; Rabelo GM; Viana AC; Alexandrino MT; Barros FA; Neto BR; Brito AA; Da Silva Costa A
    Hemodial Int; 2011 Oct; 15(4):493-500. PubMed ID: 22111817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.